|
Virtual Reality Versus Intravenous Dexmedetomidine on Maternal Anxiety, Stress, Hemodynamics, and Neonatal Outcomes During Cesarean Section
RECRUITINGN/ASponsored by Benha University
Actively Recruiting
PhaseN/A
SponsorBenha University
Started2026-01-17
Est. completion2026-07-01
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07343843
Summary
This study aims to compare the efficacy of intravenous dexmedetomidine infusion versus virtual reality (VR) in reducing maternal anxiety, stress, and hemodynamic instability during cesarean section and their effects on neonatal outcome as respiration and heart rate.
Eligibility
Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria: * Age over 18 years old. * American Society of Anesthesiologists (ASA) physical status II. * Scheduled for elective cesarean section (CS) delivery under Central Neuraxial Blockade. * Provide informed consent and agree to participate in the study. Exclusion Criteria: * Patient's refusal * Patient known have contraindications for Regional Anesthesia as infection at the site of injection, severe coagulopathy or allergy to local anesthetics. * Patient with psychiatric disorders. * Sensory impairment (blindness, deafness). * Any technical problem preventing proper fitting of the glasses to the patient face. * Patients with cognitive impairment, epilepsy or with claustrophobia * Patients with suspected eye infection * Signs of active labor. * Pregnancy related-diseases or antepartum hemorrhage. * Presence of Fetal distress.
Conditions8
AnxietyCesarean SectionDexmedetomidineHemodynamicsMaternal AnxietyNeonatal OutcomesStressVirtual Reality
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorBenha University
Started2026-01-17
Est. completion2026-07-01
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07343843